At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
D-cycloserine +2 moredrug
Likely dose
D-cycloserine 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Exposure, D-cycloserine Enhancement, and Functional Magnetic Resonance Imaging (fMRI) in Snake Phobics
In Brief
A clinical study evaluating D-cycloserine, Exposure therapy, and 1 other intervention for Specific Phobia. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The aim of the present study is to determine whether people receiving d-cycloserine and exposure therapy show different brain reactions to symptom provocation compared to people receiving placebo and exposure therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpecific Phobia
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2010
First PostedOct 2011
Primary CompletionDec 2011
TodayJul 2026
First PostedOct 12, 2011
Enrollment StartJul 1, 2010
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 14.7 years ago
Interventions
D-cycloserinedrug
50 mg d-cycloserine, oral, 1 dose
Exposure therapybehavioral
Single session graded in vivo exposure therapy, 60-180 minutes
Placebodrug
Single capsule of oral placebo, administered once 1 hr prior to exposure therapy